37 results
Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023

Thumbnail

D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters

Thumbnail

D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch

Thumbnail

D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria

Thumbnail

D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway

Thumbnail

D2.300 - Fixed Drug Eruption related to the use of NSAIDs

Thumbnail

D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test

Thumbnail

D2.303 - Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy

Thumbnail

D2.304 - Transepidermal Water Loss in Atopic Diseases

Thumbnail

D2.305 - Acute generalized exanthematous pustulosis due to iohexol with tolerance to iobitridol